The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BMEA | -87.45% | N/A | N/A | -92% |
| S&P | +14.5% | +93.32% | +14.09% | +60% |
Biomea Fusion, Inc. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.50M | -25.0% |
| Market Cap | $102.64M | -36.5% |
| Market Cap / Employee | $0.97M | -38.3% |
| Employees | 106 | 2.9% |
| Net Income | -$20.74M | 44.4% |
| EBITDA | -$20.78M | 46.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $56.22M | -50.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.30M | -10.7% |
| Short Term Debt | $0.76M | -77.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -107.10% | -34.5% |
| Return On Invested Capital | -81.95% | -1188.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$19.33M | 40.9% |
| Operating Free Cash Flow | -$19.33M | 40.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.52 | 1.85 | 1.48 | 2.35 | 96.94% |
| Price to Tangible Book Value | 3.52 | 1.85 | 1.48 | 2.35 | 96.94% |
| Enterprise Value to EBITDA | -8.54 | -3.08 | -1.71 | -1.15 | -25.05% |
| Return on Equity | -104.5% | -125.4% | -156.8% | -170.5% | 100.42% |
| Total Debt | $9.57M | $8.77M | $7.93M | $7.05M | -31.79% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
